ALK and non-small cell lung carcinoma: Even if we did not observe a significant correlation of pPD-L1 and genetic alterations beyond KRAS, this exploratory study cohort of consecutively analyzed NSCLC patients might not be ideal to study the predictive role of pPD-L1 in NSCLC patients harboring genomic alterations including EGFR, ALK and ROS1.